Biologics dont need long market exclusivity, FTC says Trapp D - A recent Federal Trade Commission report asserting that original biopharmaceutical drug manufacturers do not need lengthy exclusive marketing periods to maintain innovation has not driven supporters from a bill that would extend such protection. [more...]
